Survival after a blood clot ranges from hours to a normal lifespan, depending almost entirely on the clot’s location, its size, and how quickly treatment begins. A small clot in a leg vein that gets treated promptly carries a one-year survival rate above 85%, while a massive clot that lodges in the lungs can be fatal within minutes if it blocks blood flow to the heart. The broad answer is that most people diagnosed with a blood clot today survive well beyond the event, but even after treatment, their long-term survival stays measurably lower than that of the general population for years afterward.
The First Days and Weeks Carry the Greatest Risk
Blood clots in veins, collectively called venous thromboembolism (VTE), kill most rapidly in the first few days. A large population-based study following thousands of patients in Olmsted County, Minnesota found that overall seven-day survival after a VTE event was about 75%, and 30-day survival was about 72%. Those numbers look alarming, but they are heavily skewed by pulmonary embolism, the more dangerous form. For deep vein thrombosis (a clot in a deep leg vein) alone, seven-day survival was over 96% and one-year survival was roughly 85%. For pulmonary embolism, seven-day survival dropped to about 59%, and only around 48% of those patients were alive at one year.1JAMA Internal Medicine. Predictors of Survival After Deep Vein Thrombosis and Pulmonary Embolism: A Population-Based, Cohort Study These figures include patients of all ages and underlying conditions, and many deaths were driven by the diseases that caused the clot rather than the clot itself, particularly cancer.
Once a patient survives the initial event and begins treatment, the picture improves dramatically. During three to six months of anticoagulant therapy, the death rate for hemodynamically stable patients without major underlying disease falls below 5%.2PubMed. Long-term outcome of pulmonary embolism That distinction between stable and unstable matters enormously. A person whose blood pressure and heart function remain normal after a pulmonary embolism has a fundamentally different outlook from someone who arrives in shock.
Leg Clots Versus Lung Clots
The gap between a deep vein thrombosis in the leg and a pulmonary embolism in the lung is the single biggest factor in short-term survival. A DVT that stays in the leg veins is rarely fatal on its own. The danger comes when part of that clot breaks off and travels to the lungs. Once it reaches the pulmonary arteries, it can obstruct blood flow, strain the right side of the heart, and trigger cardiovascular collapse.
Superficial vein clots, the kind you can sometimes see or feel just beneath the skin, sit at the milder end. They are uncomfortable but were long considered harmless. That view has shifted. Research shows that somewhere between 6% and 40% of patients with a superficial vein thrombosis also harbor a deep vein clot, and symptomatic pulmonary embolism occurs in roughly 2% to 13% of them.3PubMed Central. Superficial venous thrombosis: disease progression and evolving treatment approaches A separate study using ultrasound screening found a hidden DVT in about a quarter of patients who presented with only a superficial clot.4JAMA Dermatology. Association Between Superficial Vein Thrombosis and Deep Vein Thrombosis of the Lower Extremities So even what looks like a minor surface-level clot can signal a more dangerous process underneath.
The commonly cited figure that untreated pulmonary embolism kills about 30% of patients has been questioned. That number comes from studies dating back to the 1940s, many using autopsy populations or hospitalized patients who were already very sick. When researchers looked specifically at ambulatory patients whose pulmonary embolism was missed or left untreated, the mortality and recurrence rate was actually less than 5%.5Annals of Emergency Medicine. Dispelling the Myth Relating to the Untreated Pulmonary Embolism Mortality Rate That does not mean treatment is optional. It means the old statistics overstated the danger for otherwise healthy people with smaller clots, while understating it for patients already critically ill.
Long-Term Survival Stays Below Average for Years
Surviving the first year does not put you in the clear. The Olmsted County study followed patients for up to eight years after their initial clot and found that even among those who were alive at the one-year mark, subsequent survival remained worse than expected for people of the same age and sex. At eight years, about 72% of VTE survivors were still alive compared to about 80% in the matched general population.1JAMA Internal Medicine. Predictors of Survival After Deep Vein Thrombosis and Pulmonary Embolism: A Population-Based, Cohort Study That gap held for both DVT and pulmonary embolism survivors. Part of the excess mortality comes from the conditions that triggered the clot, especially cancer and immobility from neurologic disease. Part of it comes from the clot’s own lasting effects on the body.
Recurrence Is the Shadow That Follows
A first blood clot is often not the last. Population data show that the cumulative recurrence rate reaches about 13% within the first year and climbs to roughly 30% over ten years.6PubMed. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study The risk is highest in the first six to twelve months after the original event but never falls to zero. Older age, higher body mass, cancer, and neurologic conditions all independently predict a higher chance of recurrence.
Whether a clot was “provoked” or “unprovoked” shapes how doctors think about recurrence. A provoked clot has an identifiable trigger: surgery, a long flight, a broken bone, pregnancy, or certain medications. An unprovoked clot appears without an obvious cause. The conventional wisdom has been that unprovoked clots carry a much higher recurrence risk, but a large international registry found that over 12 months, recurrence rates were actually similar between the two groups, around 3 to 4 per 100 person-years.7PubMed Central. Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD‐VTE The distinction still matters for treatment decisions, but the gap in recurrence risk may be narrower than previously thought.
Current expert guidance generally recommends that after a clot linked to a major temporary risk factor (like surgery), treatment can be stopped once the risk factor is gone. After an unprovoked clot, indefinite anticoagulation is often recommended if the risk of bleeding is low.8PubMed Central. Provoked vs minimally provoked vs unprovoked VTE: does it matter?
How Treatment Shapes the Timeline
Anticoagulants, commonly called blood thinners, are the foundation of clot treatment. They do not dissolve existing clots; instead, they prevent new clots from forming and allow the body’s own systems to gradually break down the existing one. For patients who remain on anticoagulation beyond the initial treatment period, the chance of recurrence drops, but at a cost: bleeding complications rise. Older patients who continued anticoagulation at 12 months were less likely to develop a recurrent clot in the following two years, but their rates of major bleeding and death were comparable to patients who had stopped treatment.9Blood. Thrombin Generation to Predict the Risk of Venous Thromboembolism Recurrence, Major Bleeding and Death in the Elderly: A Prospective Multicenter Cohort Study A Cochrane review of extended prophylaxis after initial treatment found that prolonged anticoagulation did not significantly reduce VTE-related mortality or overall mortality compared to placebo, while the trend toward more major bleeding did not reach statistical significance but pointed in a concerning direction.10PubMed Central. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism
Modeling studies have tried to calculate the lifetime tradeoff: extended blood thinners prevent hundreds of clots per thousand patients but also cause dozens of serious bleeding events, including fatal brain bleeds. The net survival benefit of lifelong treatment appears to be vanishingly small for most patients with unexplained clots. This is why the decision to continue or stop anticoagulation is so individualized and so difficult. It is not a simple risk-benefit calculation with an obvious winner.
For the most severe pulmonary embolisms, where the clot is large enough to cause hemodynamic collapse, anticoagulation alone may not be enough. Catheter-based interventions, which physically remove or break up the clot, have shown promise for reducing strain on the right ventricle while posing a lower bleeding risk than system-wide clot-dissolving drugs.11PubMed Central. Role of catheter-based interventions in treating pulmonary embolism In high-risk patients requiring mechanical circulatory support, catheter-based clot removal combined with that support was associated with dramatically better 60-day survival compared to other strategies in one multicenter study.12PubMed. Potential survival benefit of adjunctive catheter-based embolectomy in high-risk pulmonary embolism patients on veno-arterial extracorporeal membrane oxygenation: A multicenter retrospective study These interventions are reserved for the sickest patients, but they represent real progress for a group that previously had few good options.
Chronic Complications That Outlast the Clot
Even when a clot resolves and treatment works as planned, the body does not always return to its pre-clot state. Two chronic conditions can develop and significantly affect how long and how well someone lives afterward.
Post-thrombotic syndrome (PTS) is the more common one. It develops in the leg where the original DVT occurred, causing chronic swelling, pain, skin discoloration, and in severe cases, leg ulcers. The damaged vein valves never fully recover, and blood pools in the lower leg. In a clinical trial comparing two anticoagulant medications, roughly 40% to 50% of patients developed PTS within a few years. Among those who did, about two-thirds had mild disease, but around 10% had severe PTS that substantially impaired their daily lives.13PubMed Central. Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin PTS does not directly shorten life, but it meaningfully lowers quality of life. Patients with PTS score worse on disease-specific quality-of-life measures than those without it, and the gap widens with increasing severity.14JAMA Internal Medicine. Effect of Postthrombotic Syndrome on Health-Related Quality of Life After Deep Venous Thrombosis
Chronic thromboembolic pulmonary hypertension (CTEPH) is rarer but more dangerous. It develops when organized clot material stays lodged in the lung arteries, scarring and narrowing them permanently. The heart has to work harder to push blood through, eventually leading to right heart failure. An international registry found that patients who underwent surgery to remove the obstructing material had three-year survival around 89%, while those who could not be operated on had three-year survival of about 70%.15PubMed. Long-Term Outcome of Patients With Chronic Thromboembolic Pulmonary Hypertension: Results From an International Prospective Registry A Swedish study looking further out found that patients who survived the surgery and early recovery period had a 15-year relative survival of about 83%, meaning their life expectancy was only modestly shorter than the general population.16PubMed Central. Life expectancy after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: a Swedish single-center study CTEPH is one of the few forms of pulmonary hypertension that can be cured surgically, so early recognition matters.
When a Clot Is Found by Accident
A growing number of blood clots in the lungs are discovered incidentally, when a CT scan is done for an unrelated reason, often cancer staging. These patients had no symptoms of pulmonary embolism. It is natural to wonder whether a clot you did not even feel could still kill you.
The data are somewhat reassuring. Among cancer patients, incidental pulmonary embolism carries roughly half the mortality risk of a symptomatic one. A large study found that three-month all-cause mortality was about 11% in patients with incidental PE versus 22% in those whose PE was clinically suspected and confirmed. PE-specific death was even rarer in the incidental group, under 1%.17European Respiratory Journal. Clinical characteristics and 3-month outcomes in cancer patients with incidental versus clinically suspected and confirmed pulmonary embolism However, incidental does not mean harmless. In one cancer center series, 26% of patients with incidental PE died suddenly within 30 days of diagnosis.18PubMed Central. Incidental pulmonary embolism in cancer patients: clinical characteristics and outcome – a comprehensive cancer center experience Most of these patients had advanced malignancies, so disentangling the clot’s contribution from the cancer’s is difficult. The general approach now is to treat incidental PE in cancer patients the same way symptomatic PE would be treated.
How Age Changes the Equation
Older adults face a harder road after a blood clot. A study of elderly patients presenting to the emergency department with suspected pulmonary embolism found 30-day mortality around 14% and 90-day mortality around 21% in those with confirmed PE. In patients aged 80 and older, 30-day mortality climbed to about 19%.19PubMed. Mortality at 30 and 90 days in elderly patients with pulmonary embolism: a retrospective cohort study Troublingly, the scoring tools that help doctors identify low-risk patients performed less reliably in this older population than in the younger cohorts where they were originally validated.
A separate study specifically examining unprovoked pulmonary embolism in older adults found that none of the patients with truly unprovoked PE died within six months of admission. The patients who fared worst were those whose clot was linked to active cancer, where three-year mortality exceeded 50%.20Archives of Medical Science. Unprovoked pulmonary embolism in older adults: incidence and prognosis This suggests that in older adults, it is often the underlying disease driving the clot that determines survival rather than the clot itself.
Inherited Clotting Disorders and Life Expectancy
Many people who have had a blood clot eventually learn they carry a genetic variant that makes their blood more prone to clotting. Factor V Leiden is the most common of these, present in roughly 5% of people of European descent. Learning you carry such a mutation naturally raises the question of whether it will shorten your life.
A Dutch study tracked families with Factor V Leiden and compared their mortality to the general Dutch population. After adjusting for age, sex, and time period, there was no excess mortality among carriers. Death rates from cancer, cardiovascular disease, and stroke were all essentially identical to the general population. The researchers concluded that the mutation alone does not warrant lifelong anticoagulation.21PubMed. Mortality and causes of death in families with the factor V Leiden mutation (resistance to activated protein C) Carrying the gene makes clots more likely in specific high-risk situations, like after surgery or during pregnancy, but it does not fundamentally alter how long you will live.
The Psychological Aftermath
Discussions about survival after a blood clot tend to focus on physical outcomes, but the psychological impact is real and underappreciated. A mixed-methods study surveying and interviewing pulmonary embolism survivors found that about half experienced some degree of ongoing psychological distress. Patients recalled the pain and the moment of diagnosis as stressful, worried persistently about recurrence, and felt anxious about eventually stopping their anticoagulant medication.22PubMed Central. The psychological impact of pulmonary embolism: A mixed‐methods study Full diagnostic criteria for post-traumatic stress disorder were met in only a small percentage, but the broader experience of fear and hypervigilance was common.
Qualitative research has described a pattern some researchers call “post-thrombotic panic syndrome,” a phrase that captures the lived reality of VTE survivors. Patients describe their clot as life-changing and traumatic, report living with persistent uncertainty and fear of recurrence, and often feel poorly supported by the healthcare system after the acute phase. At the same time, some describe positive changes: a new appreciation for health, shifted priorities, and personal growth.23PubMed. “Post-thrombotic panic syndrome”: A thematic analysis of the experience of venous thromboembolism If you have survived a clot and find yourself anxious, preoccupied, or scanning your body for symptoms, you are not unusual. That experience is the norm rather than the exception.
Physical Activity and Mortality After a Clot
One of the few modifiable factors with solid evidence behind it is exercise. A study following VTE survivors over ten years found that physical activity was associated with a 28% lower risk of dying during that period. The benefit was strongest in patients whose original event was a DVT, where active patients had about a 40% lower mortality risk compared to inactive ones. Interestingly, physical activity did not appear to reduce the risk of having another clot; its benefit was specifically on overall mortality, likely through the usual cardiovascular and metabolic pathways that make exercise protective in general.24PubMed. Physical activity and risk of recurrence and mortality after incident venous thromboembolism
This finding cuts against a fear many clot survivors carry: that exercising might dislodge a clot or cause a new one. The evidence points in the opposite direction. Moving your body after a clot does not appear to increase recurrence risk, and the mortality benefit is substantial enough that staying sedentary out of fear may itself be the riskier choice.